Company Profile
MeiraGTx Stock Price, News & Catalysts
- Ticker:
- MGTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom with U
Stock performance
8.14 USD (-2.16%)
Close
Last updated: November 19, 2026
856M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, MGTX closed down 2.16% at $8.14. No new same-company headline was identified in the current news window.
Company overview
Genetic Medicines Company
MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing.
Bota-Vec
Botaretigene sparoparvovec is an AAV gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. MeiraGTx acquired global rights after completion of the Phase 3 LUMEOS study.
AAV2-hAQP1
AAV2-hAQP1 delivers the aquaporin-1 water-channel gene to salivary glands as a treatment for radiation-induced xerostomia. The program has received FDA Breakthrough Therapy designation.
Riboswitch Platform
MeiraGTx's Riboswitch technology is designed to regulate therapeutic-protein production with an oral small molecule after gene delivery. Initial programs include metabolic disease and neuropathic pain.
Manufacturing Infrastructure
The company operates gene-therapy manufacturing and quality-control facilities intended to support regulatory filings and potential commercial launches.
Future catalysts
- Submission of the bota-vec MAA for X-linked retinitis pigmentosa in December 2026.
- Submission of the bota-vec BLA in the first quarter of 2027.
- Twelve-month pivotal AQUAx2 data for AAV2-hAQP1 in radiation-induced xerostomia in mid-2027.
- Potential AAV2-hAQP1 BLA submission by the end of 2027, subject to positive AQUAx2 data.
- Initiation of the Reogen AAV-GAD Phase 3 study in the first quarter of 2027.
- Initiation of a single- and multiple-ascending-dose study of the lead riboswitch small molecule in December 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MeiraGTx (MGTX)?
MeiraGTx (MGTX) most recently closed at 8.14 USD, a -2.16% move versus the previous session.
What is the market cap of MeiraGTx (MGTX)?
MeiraGTx currently has a market capitalization of 856M USD on BioPharmSignal.
What does MeiraGTx do?
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked retinitis pigmentosa caused...
On which exchange is MGTX stock listed?
MeiraGTx (MGTX) is associated with NASDAQ, United Kingdom with U, Biopharma.
What is AAV-GAD?
Initiation of the Reogen AAV-GAD Phase 3 study in the first quarter of 2027.
Which conditions is MeiraGTx targeting with AAV-GAD?
MeiraGTx is associated with metabolic disease, genetic disease based on its company overview and current catalyst commentary.
How does MeiraGTx describe recent progress with AAV-GAD?
Initiation of the Reogen AAV-GAD Phase 3 study in the first quarter of 2027.
What is Genetic?
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions.
